Current Prospects of Rome Criteria for the Diagnosis of Irritable Bowel Syndrome

Rasha Zaid Shammout¹, Mousa Numan Ahmad*²

¹Department of Nutrition and Food Technology, Human Nutrition and Dietetics, University of Jordan, Amman11942, Jordan

Received on 31/8/2021 and Accepted for Publication on 9/10/2021.

ABSTRACT

Irritable bowel syndrome (IBS) is a worldwide health problem. It is often diagnosed by periodically-updated Rome symptom-based criteria, but the effects of recent updates on IBS diagnosis are not well clarified. This article overviews Rome III and IV IBS criteria, highlighting changes and updates that may impact IBS diagnosis. PubMed, Medline, Science Direct, Clinical trials.gov, and WHO databases were searched through to July 2021. Rome IV criteria are more restrictive, specific, and precise in patients’ diagnosis, selection, prognosis, and follow-up than Rome III criteria, in turn, IBS prevalence and number of patients with IBS-unspecified and IBS-mixed subtypes decrease, but overall symptom severity and patients’ homogeneity increase. In essence, the slight difference between Rome III and IV criteria reflects a considerable influence on IBS diagnosis, subtyping, and prevalence. Rome IV IBS patients form a homogeneous subset of Rome III IBS patients with more severe symptoms. Thus, in-depth research is warranted.

Keywords: Irritable bowel syndrome, Rome I, II, III, IV criteria.

INTRODUCTION

Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interactions (DGBI), formerly known as functional gastrointestinal disorders (FGID). It is a major health problem affecting a substantial proportion of the global population (Sperber et al., 2020 and 2021; Camilleri, 2021). The epidemiology of IBS has been studied extensively worldwide. The IBS prevalence data vary between countries due to heterogeneity in diagnostic methods or due to genuine differences between countries (Oka et al., 2020; Sperber et al., 2020 and 2021). The worldwide pooled IBS
prevalence is 9.2% when using Rome III and 3.8% when using Rome IV criteria (Oka et al., 2020).

IBS is a heterogeneous disorder with no specific laboratory or imaging tests (Irvine et al., 2017; Camilleri, 2021). The IBS etiology is poorly understood, and its diagnosis is challenging, as symptoms change over time and overlap with other disorders (Slattery et al., 2015; Irvine et al., 2017). Traditionally, IBS diagnosis is based on the exclusion of all other diseases with similar features (Oka et al., 2020). Thus, patients may undergo several unnecessary evaluations, tests, and surgeries, which unfortunately do not improve the diagnosis or treatment (Oka et al., 2020). In essence, over the years, worldwide efforts have been gathered to improve IBS understanding and diagnosis and create and define criteria for an easy and accurate diagnosis; once the diagnosis is made correctly, the treatment becomes easier and better results are expected (Palsson et al., 2020).

Nowadays, the condition is better understood, and the interactions between the brain, the gut, and their related diseases or syndromes are much clearer (Camilleri, 2021). The current IBS diagnosis is based on well-defined criteria that are updated frequently with the evolved knowledge and understanding of the condition (Rome, 2021). The Rome diagnostic criteria which are set forth by the Rome Foundation are the most adopted criteria for IBS diagnosis (Drossman, 2016; Rome, 2021). It is a culmination of the evolution of a series of iterations, started as Rome I criteria (Drossman et al., 1994), where every 6-10 years, these criteria (Rome II, III, and IV) are revised and updated based on newly emerged scientific data (Drossman et al., 2006; Schmulson and Drossman, 2017). The Rome IV criteria are the latest version published in 2016 (Drossman, 2016). This version is an evidence-based diagnosis where it is updated to be a multicultural-oriented clinical application (Schmulson and Drossman 2017; Black et al., 2020 and 2021). Although these criteria are updated to overcome the limitations of the previous criteria, the impact of these updates in both population-based and clinical studies is still a controversial topic, and more evaluation is needed.

This article provides an overview of the evidence for the Rome IBS symptom-based criteria, highlighting the Rome III and Rome IV versions over the past two decades and discussing how changes and updates of these criteria may impact IBS diagnosis.

METHODS AND SEARCH STRATEGY

An up-to-date literature search was conducted to review the evidence for the IBS symptom-based Rome criteria emphasizing the Rome III and Rome IV versions. The search was limited to the most recent English publications, focusing on those covering the last two decades. Relevant articles were principally identified through an online search of the Cochrane Central Register of Controlled Trials, PubMed, Medline, Clinical trials.gov, Google Scholar, Science Direct, ADI, and WHO database. The search process was performed using the following keywords or combinations: IBS diagnosis, IBS symptom-based criteria, IBS, Rome I criteria, Rome II criteria, Rome III criteria, and Rome IV criteria. Included articles were mainly original experimental, clinical, intervention trials, and cross-sectional research in humans. Lead review articles were also used. For search accuracy, the references’ lists of works were checked for additional publications from the major databases.

AN OVERVIEW OF THE DIAGNOSIS OF IRRITABLE BOWEL SYNDROME

Traditionally, medical diagnosis of any disease requires observed physiological or anatomical abnormalities, and then the description of the disease symptoms follows naturally (Thompson, 2006). This way of diagnosis is impossible in functional disorders since there are no observed pathophysiological defects (Lacy et al., 2016). Thus, diagnosis only relies on the words of patients and the exclusion of other diseases with clear
organic or anatomical abnormalities through extensive
tests, consultations, and surgeries, which at the end are
unfruitful and do not lead to a proper diagnosis
(Thompson, 2006; Lacy et al., 2016). This issue
considerably affects the subject’s selection and
description in randomized clinical trials, and their results
end up with uncertain applicability. In 1988, for example,
a critique by Klein et al., (1988) of 43 clinical trials of
treatment concluded that “not a single IBS treatment trial
reported to that date used an adequate operational
definition of IBS”. Therefore, the need for a more positive
approach with unified criteria for diagnosis and
descriptions is a global need and a must for functional
disorders, including IBS. The evolution of the symptom-
based criteria for IBS has started by Manning criteria
(Manning et al., 1978), followed by the highly accepted
Rome criteria that are published by Rome Foundation
every 6-10 years (Drossman, 2016; Palsson et al., 2016;
Whitehead et al., 2017). Table 1 shows a summary of the
diagnostic criteria of IBS and the year of emergence.

Table 1: Reported diagnostic criteria of irritable
bowel syndrome and related disorders

| Reference            | Diagnostic criteria                                      |
|----------------------|---------------------------------------------------------|
| Manning et al., 1978 | Manning Criteria for IBS                                |
| Kruis et al., 1984   | Kruis Criteria for IBS                                  |
| Thompson et al., 1989| Rome I Guidelines for IBS                               |
| Drossman et al., 1990| Rome I Classification System for FGID                  |
| Thompson et al., 1992| Rome I Criteria for IBS                                 |
| Drossman et al., 1994| Rome I Criteria for FGID                                |
| Thompson et al., 1999| Rome II Criteria for IBS and FGID                       |
| Drossman et al., 2006| Rome III Criteria                                       |
| Drossman et al., 2016| Rome IV Criteria                                       |

Abbreviations: IBS: irritable bowel syndrome; FGID: functional gastrointestinal disorders

The Rome Foundation, which is an independent, not-
for-profit organization, based in North Carolina, United
States, leads the scientists and efforts worldwide in the
creation and developments of the Rome Criteria (Rome,
2021). The Rome Foundation aims to support the creation
of educational information and scientific data that help in
the diagnosis and treatment of all FGID, later known as
DGBI, including IBS. It also aims to promote the
legitimization and global recognition of DGBI, advance
the scientific understanding of their pathophysiology,
optimize patient clinical management, and develop and
provide educational resources and tools to accomplish
these goals (Rome, 2021). Although the Rome criteria as
symptom-based criteria are initially developed to guide
researchers, these criteria nowadays are widely used in
research, clinical, and prevalence studies (Drossman,
2016). It has also undergone several revisions
periodically to make them more clinically useful and
relevant (Sperber et al., 2017; Lin and Chang, 2020).

International guidelines recommend a positive
diagnosis of symptom-based diagnostic criteria, such as
the Rome Criteria, and minimization of exhaustive and
expensive investigations (Whitehead et al., 2017). In
clinical practice, besides symptoms-based criteria, extra
evaluations may enhance the diagnosis with little cost,
particularly investigation of the patient’s history,
including diet, medications, surgeries, and psychosocial
status (Ford et al., 2018). Conducting a complete blood
count, complete metabolic panel, and measuring C-
reactive protein are also reasonable according to current
literature (Palsson et al., 2020). Checking on some “red
flags” known as warning signs for other diseases, such as
onset at greater than 50 years of age, anemia,
haematochezia, unintentional weight loss, family history
of colorectal cancer or inflammatory bowel disease are
additional reasonable evaluations (Lacy and Patel 2017;
Ford et al., 2018). The thyroid profile should be obtained
only if the clinical suspicion for thyroid disease is high
and exclusion of celiac disease and inflammatory
conditions may be recommended, especially in non-
constipated patients with IBS (Begtrup et al., 2013). Once
the diagnostic criteria are satisfied, the absence of
warning symptoms, normal blood tests, and historical and
physical examinations suggest IBS, the risk for
overlooking organic disease may be as low as 1-3%
(Palsson et al., 2020). In practice, in cases where no
warning symptoms appear, the IBS expert consensus
states that the evaluation should be limited to fulfilling the
Rome criteria (Palsson et al., 2020).

THE ROME DIAGNOSTIC CRITERIA

In 1988, a group of international experts met in
Rome- Italy, to discuss all of the FGID, later known as
DGBI, including IBS (Thompson et al., 1999). Their goal
was to classify the FGID using a symptom-based
classification scheme and highlight the fact that patients
report symptoms despite a lack of physiological,
chemical, or radiological abnormalities. The expert team
used a “Delphi” method of decision making, which
depends on fostering the team to produce constancy and
consensus in opinion, to answer tough clinical questions
that could not be answered through available scientific
evidence at the time, and ultimately present and publish
the results of the meeting (Thompson et al., 1989). The
discussions and recommendations concluded in the
publication of the Rome guidelines for IBS (Thompson et
al., 1990), classification criteria for FGID (Thompson et
al., 1999), and the following years, the Rome I criteria for
IBS was published in 1992 (Thompson et al., 1992), and
in 1994 the FGID was published too (Drossman et al.,
1994). Table 2 presents the different versions of Rome’s
diagnostic criteria of irritable bowel syndrome.

The Rome I criteria for IBS diagnosis need at
least three months of continuous or recurrent abdominal
pain that is relieved with defecation or associated with a
change in stool consistency with at least 2 of the
following on at least 25% of days: altered stool frequency,
altered stool form, altered stool passage, the passage of
mucus, bloating or abdominal distension (Drossman et
al., 1994; Thompson et al., 1999). In the early 1990s,
these publications formed the cornerstone that increased
the awareness and shaped the future research, diagnosis,
and treatment of FGID, especially the IBS (Thompson et
al., 1989; Thompson et al., 1992; Drossman et al., 1994).
By the end of the 1990s, the use of diagnostic criteria and
the concept of FGID classification were promoted and
adopted by the United States Food and Drug
Administration, which recommended the use of the Rome
criteria for IBS diagnostic for pharmaceutical studies
(Whitehead et al., 2017).

Table 2: Different versions of Rome Diagnostic criteria of irritable bowel syndrome

| Criteria          | Diagnosis criteria                                                                 | IBS*- subtype          |
|-------------------|------------------------------------------------------------------------------------|------------------------|
| Rome I            | Abdominal pain and discomfort that is relieved with defecation and/or associated    | Not defined            |
| (Thompson et al., | with a change in frequency of stool, and/or associated with a change in the        |                        |
| 1992)             | consistency of stool, and two/more of the following at least on one-fourth of      |                        |
|                   | occasions/days:                                                                  |                        |
|                   | • Altered stool frequency                                                         |                        |
|                   | • Altered stool form                                                             |                        |
|                   | • Altered stool passage                                                          |                        |
|                   | • Passage of mucus and/or bloating or feeling of abdominal distension.            |                        |
Abdominal pain or discomfort for at least twelve weeks that need not be consecutive in the preceding twelve months associated with two or more of the following:
- Relieved with defecation and/or
- Onset associated with a change in frequency of stool and/or
- Onset associated with a change in the appearance of stool.

Rome III criteria are different from Rome I and II in using more evidence-based rather than consensus-based data (Drossman et al., 2006). The most significant change is having a model for IBS classification into different subtypes based on stool consistency rather than stool frequency. The IBS subtypes are IBS-C, IBS-D, IBS-M, and IBS-U, where C, D, M, and U refer to constipation, diarrhea, mixed, and unsub-typed (Longstreth et al., 2006). Another significant change is the removal of bloating as a primary symptom from the definition. This change is based on the view that bloating as a symptom is neither sensitive nor specific for IBS alone, and it is a widespread symptom of other diseases (Longstreth et al., 2006).

The IBS Rome III criteria are widely accepted and fairly well implemented worldwide (16). However, given the emerging science and information on the IBS pathophysiology in the 10 years since the launch of Rome III, the Rome Foundation announced the Rome IV criteria in 2016 with slight changes. The description of IBS as DGBI replaces the term FGID and the role of the microbiome, intestinal permeability, and inflammatory signaling pathways in symptom development is recognized (Barandouzi et al., 2021). Besides the inclusion of new treatment options, such as the use of eluxadoline, linaclotide, rifaximin, probiotics, and low
fermentable oligosaccharides, monosaccharides, and polyols diets (Herndon et al., 2020). In Rome IV criteria, IBS is defined as recurrent abdominal pain on at least one day per week on average, over the past 3 months, which must be associated with two or more of the following symptoms: abdominal pain related to defecation and a change in bowel frequency and stool form (Schmulson and Drossman, 2017).

KEY CHANGES IN ROME DIAGNOSTIC CRITERIA

Over the years, the Rome criteria for IBS diagnosis are periodically revised and updated. Each version has undergone several main changes that are summarized in the following key points. Firstly, in Rome IV, the word onset is removed compared to Rome II and III, as the onset of abdominal pain is not concurring with a change in stool frequency or form in all patients (Schmulson and Drossman, 2017). Secondly, the criteria are changed from "abdominal pain relieved with defecation" in Rome I and II or "improvement of abdominal pain with defecation" in Rome III to "abdominal pain related to defecation" in Rome IV as some IBS patients reported worsening of abdominal pain after defecation (Drossman, 2016; Herndon et al., 2020; Black et al., 2021).

Thirdly, the term “discomfort” is removed from Rome III, as some languages do not have synonym words for discomfort, or it has different meanings in different languages. Thus, this term is considered nonspecific and ambiguous, and some patients consider the “discomfort” to be mild pain, while others explain it as urgency or bloating (Schmulson and Drossman, 2017). This change considers pain as a characteristic factor for IBS to help distinguish it from other functional bowel disorders, such as functional constipation and functional diarrhea that have little or no pain compared to IBS (Drossman, 2016). In essence, it is intended to make Rome IV more culturally adapted and well understood globally. Fourthly, the minimum abdominal pain frequency required for diagnosis is increased from three days a month in the last three months in Rome III to once a week in Rome IV. This change is based on the findings of large population studies that aim to increase the sensitivity and specificity of the criteria (Palsson et al., 2016; Whitehead et al., 2017; Palsson et al., 2020). As a result of this change, some studies show a decrease in IBS prevalence, while in others, the prevalence is unchanged (Vork et al., 2018; Aziz et al., 2018).

Fifthly, concerning the IBS subtypes, Rome III is the first to classify IBS patients into subtypes. This classification is very useful as it helps focus treatment on the predominant and the most bothersome symptom (Algera et al., 2019). In Rome III, the IBS is divided into IBS-D, IBS-C, IBS-M, and IBS-U based on the proportion of all bowel movements that are hard/lumpy or loose/watery, considering all bowel movements and not only the symptoms. Patients can have large periods with normal stool consistency, and a large number of patients are classified into IBS-U. Besides, it has been shown that IBS subtypes will be more reliable if based only on the days of abnormal bowel movements and not on all bowel movements (Lacy et al., 2017). Therefore, the Rome IV criteria change the subtypes based on the patient’s perception of their predominant type of abnormal stool consistency rather than the frequency of defecation. The Bristol Stool Form Scale (BSFS) is often used for this purpose (Heaton and Lewis, 1997). This scale is a visual tool and a convenient way for patients to describe their bowel habits, basically developed in the 1990s in the Bristol Royal Infirmary in England (Heaton and Lewis, 1997).

In BSFS, stool types 1 and 2 are being associated with constipation, while stool types 6 and 7 are associated with diarrhea, besides stool type 5 to some degree (Heaton and Lewis, 1997). Stool types 3 and 4 are considered normal (Heaton and Lewis, 1997). Thus, in Rome IV, patients with IBS-C have >25% of their bowel
movements associated with BSFS 1 or 2, while those with IBS-D have >25% of their bowel movements associated with BSFS 6 or 7. Patients with the mixed subtype of alternating constipation and diarrhea (IBS-M) have >25% of their bowel movements associated with BSFS 1 or 2 and >25% of their bowel movements associated with BSFS 6 or 7 (Lacy and Patel, 2017; Ford et al., 2020). In Rome IV, the predominant term is add/ed to types, and patients' perceptions of the predominant type of abnormal consistency of stools are the determinants of the types. This modification reduces the IBS-U group and identifies other IBS subtypes (Drossman, 2016; Ford et al., 2018). Table 3 exhibits a summary of the comparison between IBS subtypes in Rome III versus Rome IV.

### Table 3: Subtypes of irritable bowel syndrome in Rome III vs. Rome IV.

| Rome III criteria* (Drossman et al., 2006) | Rome IV criteria** (Drossman et al., 2016) |
|-------------------------------------------|---------------------------------------------|
| **IBS**-**C** *(IBS with constipation)*    | **IBS**-**C** *(IBS with predominant constipation)* |
| Hard/lumpy stools                          | >25% of bowel movements with Bristol stool form type 1–2 and <25% of bowel movements with Bristol stool form types 6–7 |
| >25% and loose/watery stools <25% of bowel movements | |
| **IBS**-**D** *(IBS with diarrhea)*        | **IBS**-**D** *(IBS with predominant diarrhea)* |
| Loose/watery stools                         | >25% of bowel movements with Bristol stool form type 6–7 and <25% of bowel movements with Bristol stool form types 1–2 |
| >25% and hard/lumpy stools <25% of bowel movements | |
| **IBS**-**M** *(IBS mixed)*                | **IBS**-**M** *(IBS with mixed bowel habits)* |
| Hard/lumpy stools                          | >25% of bowel movements with Bristol stool form type 1–2 and >25% of bowel movements with Bristol stool form type 6–7 |
| >25% and loose/watery stools >25% of bowel movements | |
| **IBS**-**U** *(IBS-unsub-typed)*          | **IBS**-**U** *(IBS-unclassified)* |
| Insufficient abnormality of stool consistency to meet criteria for IBS-C, D, and M | Patients who meet criteria for IBS, but do not fall into one of the other three subgroups according to Bristol stool form type |

*Classification based on all bowel movements in last month. **Classification based on only days with symptomatic bowel movement. IBS: Irritable bowel syndrome.

### VALIDITY OF ROME DIAGNOSTIC CRITERIA

Since there is no specific biomarker for the IBS diagnosis, the sensitivity and specificity of a diagnostic tool cannot be tested as per standard conventional measures, especially in samples of the general population (Whitehead and Drossman, 2010; Algera et al., 2019). There is no gold standard to allow independent confirmation of diagnosis. Sensitivity across the different IBS criteria ranges from 0.4 to 0.9 depending on the experience of the practitioners and researchers, possibly reflecting variation in confidence to use criteria for positive diagnosis (Whitehead et al., 2006; Whitehead and Drossman, 2010).

In general, all of the known IBS diagnostic criteria have modest specificity of about 0.7 to diagnose IBS in patients with the organic gastrointestinal disease, as the symptoms experienced in IBS are overlapped with other gastrointestinal disorders (Whitehead and Drossman, 2010). This specificity can be increased to 0.9 when extensive evaluation is done for the patient to look for red flags such as anemia, rectal bleeding, and weight loss that are present only in just 3% of patients and used to exclude other organic diseases (Whitehead and Drossman, 2010). In secondary care, the sensitivity of the
Current Prospects of Rome Criteria………..

Rome III criteria is 68.8%, and specificity is 79.5% (Whitehead et al., 2006). However, as mentioned earlier, enhancement of the performance of criteria is attained when more investigation is done to assess the patient’s clinical history, including the absence of nocturnal stools, the presence of anxiety, depression, or extraintestinal symptoms, and a normal full blood count and C-reactive protein (Thompson et al., 1999).

A frequent criticism of the Rome III criteria is that they are not validated. Therefore, the Rome Foundation sponsored several validation studies for the Rome IV criteria before its publication (Palsson et al., 2016). The threshold of IBS symptoms such as pain and altered stool frequency is based on experts’ opinions and not on evidence-based studies. These symptoms are common in a healthy individual and only may be an issue in IBS when there are abnormal pain and frequency. Hence, in Rome IV, the threshold of pain frequency is changed from 3 days per month to once per week to have a positive IBS diagnosis; this change is based on a study that surveyed the frequency of IBS symptoms in a sample of 1665 from the USA (Palsson et al., 2016; Drossman, 2016).

In clinical validation, where there is no biological marker for IBS, the symptom criteria are validated against one of the two reference standards, diagnosis by exclusions done by expert practitioners or by negative endoscopy in patients with abdominal pain (Whitehead and Drossman, 2010). The sensitivity and specificity of Rome III and IV criteria are clinically tested in a study involving 427 patients and showed that, compared to Rome III, Rome IV correctly identify a fairly lower percentage of patients diagnosed with IBS (sensitivity), but they are less likely to identify a person wrongly as having IBS (specificity) (Whitehead and Drossman, 2010). Current data show that Rome IV criteria are more specific and less sensitive than Rome III criteria as evidenced by a population-based study evaluating the prevalence of IBS using both criteria among 5931 individuals from the USA, UK, and Canada (Palsson et al., 2020). In that study, the prevalence of IBS reduced from 10.7% when using Rome III to 5.7% when using Rome IV (Palsson et al., 2020).

IMPACTS OF UPDATES OF ROME III TO ROME IV ON CLINICAL PRACTICE

Despite the minor change in the IBS diagnostic criteria between Rome III and IV, these changes have a considerable influence on the IBS subtyping, prevalence, specificity, sensitivity, and clinical management (Whitehead and Drossman, 2010; Whitehead et al., 2017; Vork et al., 2018). In fact, since the launch of the Rome IV criteria in 2016, several studies evaluated the effect of possible changes on the IBS prevalence and other factors (Vork et al., 2018; Aziz et al., 2018; Wang et al., 2019; Lin and Chang, 2020). Vork et al., (2018) conducted a large cohort study to determine the IBS prevalence using different tools and the differences between Rome IV-positive and Rome IV-negative, the results showed that the Rome IV IBS population is likely to reflect a subgroup of Rome III IBS patients, with more severe gastrointestinal symptomatology, psychological comorbidities, and lower quality of life. This implies that results from Rome III IBS studies may not be directly comparable to those from Rome IV IBS populations (Vork et al., 2018).

On the other hand, Aziz et al., (2018) examined how the change in IBS criteria impacts the clinical characteristics and pathophysiological factors of the disease. They revealed that most Rome III-positive IBS patients who are seeking healthcare fulfill the Rome IV IBS criteria, and Rome IV-positive subjects are significantly more likely to have poorer quality of life, greater pain severity, bloating, and fatigue than Rome IV-negative subjects (Aziz et al., 2018). In China, a study by Wang et al., (2019) that used the Rome IV criteria showed that the number of IBS patients is reduced, accompanied by an increase in the percentage of unspecified functional
bowel disorders. Besides, the updated criteria also have great impacts on clinical parameters, sleep quality, and the psychological state of IBS patients. They concluded that a large-scale evaluation is needed before adopting the Rome IV criteria (Wang et al., 2019).

In early 2020, Black et al., (2020) published important results of the largest survey study that evaluated the impact of change between Rome III and Rome IV and surveyed 1375 adults in the United Kingdom who self-identified for having IBS. They found that about 78.9% of the participants met the Rome III criteria for IBS, whereas only 59.1% of the sample met the Rome IV criteria (Black et al., 2020). Further, many of those who did not meet the Rome IV criteria met other functional disorders that overlap in symptoms with IBS, such as functional constipation, functional diarrhea, and functional abdominal bloating or distention (Black et al., 2020 and 2021). Similar results are also reported earlier elsewhere (Aziz et al., 2018; Vork et al., 2018). In this context, Black et al., (2020) also showed that patients who met Rome IV criteria have more severe symptoms that are more likely to interfere with activities of daily living.

On the other hand, to compare the IBS prevalence between different studies using different tools, two large metanalyses are published in 2020 for the worldwide prevalence of IBS. The first metanalysis showed that the pooled prevalence of IBS is 9.2% in 53 studies that used the Rome III criteria, and is only 3.8% in six studies that used the Rome IV criteria from 34 countries (Oka et al., 2020). The second metanalysis about the worldwide prevalence of FGID, including IBS, showed similar results of less prevalence of IBS in Rome IV vs. Rome III in both internets (4.1% vs. 10.1%) and household surveys (1.5% vs. 3.5%) (Sperber et al., 2021). The reduction of IBS prevalence in studies that used Rome IV is not surprising, as the frequency of pain needed for positive IBS diagnosis increased from three times per month to at least one time per week, and thus the specificity is increased somehow at the expense of the sensitivity (Whitehead et al., 2017). This is the primary aim of the Rome Foundation as these criteria are a key factor in the research. This is especially important for IBS patients' inclusion in clinical and pharmaceutical trials, as more homogenous samples often lead to more precise results (Black et al., 2020).

The subtyping in the Rome III criteria is based on all bowel movements, whereas in the Rome IV criteria, it is dependent only on abnormal movements. This change affects both clinical practice and epidemiological studies, as in Rome IV criteria, the IBS subtype depends on the patients' perception of their predominant type of abnormal stool consistency, which leads to reducing the number of patients with (IBS-U) and (IBS- M), as classified by Rome III. Further, this may affect the clinical management, as several medications, such as linaclotide and lubiprostone, are approved by the FDA only for the treatment of IBS-C, while other medications, like eluxadoline and rifaximin, are approved only for IBS-D, and none are approved for the treatment of IBS-M or IBS-U (Schmulson and Drossman, 2017; Black et al., 2020; Oka et al., 2020).

Currently, the treatments for IBS symptoms are not approved based on the criteria of diagnosis, rather the treatments are designed for the most bothersome symptoms, regardless of the criteria used (Black et al., 2020). Black et al., (2020) concluded that when patients are not diagnosed with IBS by Rome IV criteria, most of them are diagnosed with other functional gastrointestinal disorders, such as functional diarrhea or functional constipation, that share overlapped symptoms with IBS. Thus, practitioners may use the same medications for the same symptoms. Indeed, this matter merits further research (Lin and Chang, 2020).
CONCLUSION
There is a scarcity of studies that implement Rome IV criteria in the prevalence of IBS, compared to Rome III criteria that are used extensively in many epidemiological studies in the last 15 years. Despite this, the current evidence shows that the prevalence of IBS decreases, and the overall severity of IBS symptoms increases when Rome IV criteria are used, rather than Rome III criteria. The benefit of Rome IV can be seen in research and clinical application for being more specific and thus more precise in patient’s diagnosis, selection, prognosis, and follow-up in clinical intervention trials. Nevertheless, Rome IV as more restrictive criteria might be less suitable than Rome III for population-based epidemiological surveys. Besides, for the clinical application and treatments of IBS patients, the current evidence does not assess the difference in treatments for different patients with IBS diagnosed on different criteria. These aspects need in-depth evaluation in future studies.

ACKNOWLEDGEMENTS
The authors would like to thank the University of Jordan, Amman, Jordan.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
Algera, J., Colomier, E., Simrén, M. (2019). The dietary management of patients with irritable bowel syndrome: a narrative review of the existing and emerging evidence. Nutrients, 11(9):2162. doi:10.3390/nu11092162
Aziz, I., Tornblom, H., Palsson, O.S., Whitehead, W.E., Simrén. M. (2018). How the change in IBS criteria from Rome III to Rome IV impacts clinical characteristics and key pathophysiological factors. American Journal of Gastroenterology. 113(7):1017-1025. DOI: 10.1038/s41395-018-0074-z.
Barandouzi, Z.A., Lee, J., Maas, K., Starkweather, A.R., Cong, X.S. (2021). Altered gut microbiota in irritable bowel syndrome and its association with food components. Journal of Personal Medicine. 11(1):35. https://doi.org/10.3390/jpm11010035.
Begtrup, L.M., Engsbro, A.L., Kjeldsen, J., Larsen, P.V., de Muckadell, O.S., Bytzter, P., et al. (2013). A positive diagnostic strategy is non-inferior to the strategy of exclusion for patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology. 11(6):956962. doi:10.1016/j.cgh.2012.12.038.
Black, C.J., Craig, O., Gracie, D.J., Ford, A.C. (2021). Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 70(6): 1110–1116. https://doi.org/10.1136/gutjnl-2020-322519.
Black, C.J., Yiannakou, Y., Houghton, L.A., Ford, A.C. (2020). Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clinical Gastroenterology and Hepatology. 18(2):392-398, e2. DOI: 10.1016/j.cgh.2019.05.037.
Camilleri, M. (2021). Diagnosis and treatment of irritable bowel syndrome: a review. Journal of American Medical Association. 325(9): 865–877. https://doi.org/10.1001/jama.2020.22532.
Drossman, D.A. (2016). Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 150:1262-1279. DOI: 10.1053/j.gastro.2016.02.032.
Drossman, D.A., Corazziari, E., Delvaux, M., Spiller, R.C., Talley, N.J., Thompson, W.G., et al. (2006). Rome III: The Functional Gastrointestinal Disorders. VA: Degnon Associates, McLean.
Drossman, D.A., Funch-Jensen, P., Janssens, J., Talley, N.J., Thompson, W.G., Whitehead, W.E. (1990). Identification of subgroups of functional bowel disorders. Gastroenterology International. 3:159-172.

Drossman, D.A., Richter, J.E., Talley, N.J., Thompson, G.W., Corazziari, E., Whitehead, W.E. (1994). The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment-A Multinational Consensus. Boston, Little Brown, and Co.

Ford, A.C., Moayyedi, P., Chey, W.D., Harris, L.A., Lacy, B.E., Siato, Y.A., et al. (2018). American College of Gastroenterology monograph on the management of irritable bowel syndrome. American Journal of Gastroenterology. 113(2):1-18. https://doi.org/10.1038/s41395-018-0084-x.

Herndon, C.C., Wang, Y.P., Lu, C.L. (2020). Targeting the gut microbiota for the treatment of irritable bowel syndrome. Journal of Medical Science. 36(3):160-170. https://doi.org/10.1002/kjm2.12154.

Irvine, A.J., Chey, W.D., Ford, A.C. (2017). Screening for celiac disease in irritable bowel syndrome: an updated systematic review and meta-analysis. American Journal of Gastroenterology. 112(1):65-76. DOI: 10.1038/ajg.2016.466.

Klein, K.B. (1988). Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology. 95(1):232-241. DOI: 10.1016/0016-5085(88)90319-8.

Kruis, W., Thieme, C., Weinzierl, M., Schüssler, P., Holl, J., Paulus, W. (1984). A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology. 87(1):1-7. PMID: 6724251.

Lacy, E., Mearin, F., Chang, L., Lembo, A.J., Simrén, M., Spiller, R., et al. (2016). Bowel disorders. Gastroenterology. 150(6):1393-1407. https://doi.org/10.1053/j.gastro.2015.02.031.

Lacy, E., Patel, K. (2017). Rome criteria and a diagnostic approach to irritable bowel syndrome. Journal of Clinical Medicine. 6(11):99. DOI: 10.3390/jcm6110099.

Lewis, S.J., Heaton, K.W. (1997). Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology. 32(9):920-924. DOI: 10.3109/00365529709011203.

Lin, L., Chang, L. (2020). Benefits and pitfalls of change from Rome III to Rome IV criteria for irritable bowel syndrome and fecal incontinence, Clinical Gastroenterology and Hepatology. 18(2):297-299. DOI: 10.1016/j.cgh.2019.10.004.

Longstreth, G.F., Thompson, W.G., Chey, W.D., Houghton, L.A., Mearin, F., Spiller, R.C. (2006). Functional bowel disorders. Gastroenterology. 130(5):1480–1491. doi:10.1053/j.gastro.2005.11.061.

Manning, A.P., Thompson, W.G., Heaton, K.W., Morris, A.F. (1978). Towards positive diagnosis of the irritable bowel. British Medical Journal. 2(6138):653–954. https://doi.org/10.1136/bmj.2.6138.653.

Oka, P., Heather, P., Barberio, B., Black, C.J., Savarino, E.V., Ford, A.C. (2020). The global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterology and Hepatology. 5(10):908-917. doi:10.1016/S2468-1253(20)30217-X.

Palsson, O.S., Whitehead, W., Toriblom, H., Sperber, A.D., Simren, M. (2020). Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 158(5):1262-1273. DOI: 10.1053/j.gastro.2019.12.021.

Palsson, O.S., Whitehead, W.E., van Tilburg, M.A.L., Chang, L., Chey, W., Crowell, M.D., et al. (2016). Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterology. 150(6):1481–1491. https://doi.org/10.1053/j.gastro.2016.02.014.

Rome foundation official website, www.theromefoundation.org, accessed July 2021.

Schmulson, M.J., Drossman, D.A. (2017). What is new in Rome IV. Journal of Neurogastroenterology and Motility. 23(2):151-163. doi: 10.5056/jnm16214.
Current Prospects of Rome Criteria

Slattery, S.A., Niaz, O., Aziz, Q., Ford, A.C. (2015). Farmer, A.D. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhea. *Alimentary Pharmacology and Therapeutics*. 42(1): 3–11. https://doi.org/10.1111/apt.13227.

Sperber, A.D., Bangdiwala, S.I., Drossman, D.A., Ghoshal, U.C., Simren, M., Tack, J., et al. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. *Gastroenterology*. 160(1):99-114. e3. DOI: 10.1053/j.gastro.2020.04.014.

Sperber, A.D., Bangdiwala, S.I., Drossman, D.A., Ghoshal, U.C., Simren, M., Tack, J., et al. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. *Gastroenterology*. 160(1): 99–114. e3. https://doi.org/10.1053/j.gastro.2020.04.014.

Thompson, W.G. (2006). The road to Rome. *Gastroenterology*. 130(5):1552–1556. doi:10.1053/j.gastro.2006.03.011.

Thompson, W.G., Creed, F.H., Drossman, D.A., Heaton, K.W., Mazzaacca, G. (1992). Functional bowel disorders and functional abdominal pain. *International Journal of Gastroenterology*. 5:75-91.

Thompson, W.G., Dotevall, G., Drossman, D.A., Heaton, K.W., Kruis, W. (1989). Irritable bowel syndrome: guidelines for the diagnosis, *International Journal of Gastroenterology*. 2:92-95.

Thompson, W.G., Longstreth, G.F., Drossman, D.A., Heaton, K.W., Irvine, E.J., Muller-Lissner, S.A., et al. (1999). Functional bowel disease and functional abdominal pain, *Gut*. 45(S2): 1143-1147. https://doi.org/10.1136/gut.45.2008.i43.

Vork, L., Weerts, Z.Z.R.M., Mujagic, Z., Kruimel. J.W., Hesselink, M.M., Muris, J.W.M., et al. (2018). Rome III vs Rome IV criteria for irritable bowel syndrome: a comparison of clinical characteristics in a large cohort study. *Journal of Neurogastroenterology and Motility*. 30:2. DOI: 10.1111/jnmo.13189.

Wang, B., Zhao, W., Zhao, C. (2019). What impact do Rome IV criteria have on patients with IBS in China? *Scandinavian Journal of Gastroenterology*. 54(12):1433-1440. doi:10.1080/00365521.2019.1698650.

Whitehead, W.E., Drossman, D.A. (2010). Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. *American Journal of Gastroenterology*. 105(4):814-820. DOI: 10.1038/ajg.2010.56.

Whitehead, W.E., Palsson, O.S., Feld, A.D., Levy, R.L., Kroff, M.V., Turner, M.J. (2006). Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*. 24(1):137–146. DOI: 10.1111/j.1365-2036.2006.02956.x.

Whitehead, W.E., Palsson, O.S., Simren, M. (2017). Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? *Experimental Review in Gastroenterology and Hepatology*. 11(4),281-283. DOI: 10.1080/17474124.2017.1292130.

Rasha Zaid Shammout and Mousa Numan Ahmad
المملوء 1

ملخص

متلازمة القولون العصبي هي مشكلة صحية عالمية. وغالبًا ما يتم تشخيصها من خلال المعايير المستندة إلى أعراض روما المحتملة بشكل مزدوج، ولكن آثار التحديات الأخيرة على تشخيص القولون العصبي لم يتم توضيحها بشكل جيد. ويلقي هذا المقال نظرة عامة على معايير روما الثالثة والرابعة لمتلازمة القولون العصبي، ويسلط الضوء على التغييرات والتحديات التي قد تؤثر على تشخيصه. وتم البحث في قواعد البيانات العالمية الرئيسية حتى يوليو 2021. وكانت معايير روما الرابعة أكثر تقدما وتحديدا ودقة في تشخيص المرضى واتخاذهم بالتفاوت بهم وتبادلهم مقارنة بمعايير روما الثالثة، وفي المقابل، ينخفض انتشار متلازمة القولون العصبي ونوع المرضى الذين يعانون من أنواع فرعية غير محددة ومخطئة من القولون العصبي، ولكن تزداد شدة الأعراض الإجمالية والتجانس لدى المرضى. وفي الأصل، بعكس الاختلافات الطفيفة بين معايير روما الثالثة والرابعة تأتي كبرى على تشخيص القولون العصبي، والتصنيف الفرعي، والانتشار. وكشف المرضى المشتبهين بمعايير روما الرابعة مجموعة فرعية متجانسة من المرضى المشتبهين بمعايير روما الثالثة مع أعراض أكثر حد، وبالتالي، فإن البحث المتعلق له ما يبرو.

الكلمات الدالة: متلازمة القولون العصبي، معايير روما الأولى والثانية والثالثة والرابعة.

* التواصل: الأستاذ الدكتور موسى نعما نعما أحمد، الجامعة الأردنية، قسم التغذية والتصنيع الغذائي، تغذية الإنسان والحيوان، عمان 11942، الأردن، mosnuman@ju.edu.jo.